Great find, Talon, from that new article 8/1/17 re Dr George Perry. Particularly enjoyed these quotes and how they may relate to Anavex 2-73:
"Perry himself has published around 1,000 pieces on Alzheimer’s disease, making him the nation’s leading Alzheimer’s researcher. He is currently the editor-in-chief of the Journal of Alzheimer’s Disease."
"After 30 years and $24 billion invested in efforts to reduce plaques, Perry’s hypothesis is controversial. Investment, however, cannot truncate the scientific process."
"Just like other aspects of physical health that deteriorate with age, “you can do a lot to do reduce your chances of having the disease,” Perry explained. When patients present with Alzheimer’s, he said, many of the cells in their body – not just the brain – show signs of stress."
"He recommends reducing the oxidative stress within the body with the tried and true elements of “good, clean living:” lots of fruits and vegetables, exercise, reduced stress, and a reason to live decrease the likelihood of Alzheimer’s by 50%, Perry said."
Interesting correlation (from the nation's leading Alzheimer's researcher) to Anavex's approach of reducing oxidative stress?
6:34 in the June presentation: "It's also been shown with our drug that very nicely dose dependently it reduces oxidative stress"
Slide 13 from June 2017:
"Confirmed effects of Sigma 1 receptor activation.... Reduces Oxidative stress" and "Anavex 2-73 is an orally-available, small molecule activator of the Sigma 1 receptor restoring cellular homeostasis by targeting protein misfolding, oxidative stress, mitochondrial dysfunction, inflammation and cellular stress, factors in both neurodegenerative and neurodevelopmental diseases."
And as we all know, last November Dr Perry had this to say about Anavex's 41 week data: "Although this is an open label study with 32 patients, I have never seen mild-to-moderate Alzheimer’s patients maintain near baseline cognitive and activities of daily living function and positive correlation with all other measures over a 41-week trial period in any prior study with an approved or experimental drug. It is quite plausible that complex CNS diseases like Alzheimer’s may require a comprehensive approach, including restoration of cellular homeostasis.”
